Nanotherapeutics, Inc. - Product Pipeline Review - 2016

This report is available at upto 25% Discount. To avail discount please contact at +1-888-391-5441 / sales@reportsandreports.com.

Global Markets Direct’s, ‘Nanotherapeutics, Inc. - Product Pipeline Review - 2016’, provides an overview of the Nanotherapeutics, Inc.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Nanotherapeutics, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

• The report provides a snapshot of the pipeline therapeutic landscape of Nanotherapeutics, Inc.
  
• The report provides overview of Nanotherapeutics, Inc. including its business description, key facts, and locations and subsidiaries
  
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  
• The report assesses Nanotherapeutics, Inc.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  
• The report features Nanotherapeutics, Inc.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

• Evaluate Nanotherapeutics, Inc.’s strategic position with total access to detailed information on its product pipeline
  
• Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  
• Identify and understand important and diverse types of therapeutics under development for Nanotherapeutics, Inc.
  
• Identify potential new clients or partners in the target demographic
  
• Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  
• Devise corrective measures for pipeline projects by understanding Nanotherapeutics, Inc.’s pipeline depth and focus of pipeline therapeutics
  
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

This report is available at upto 25% Discount. To avail discount please contact at +1-888-391-5441 / sales@reportsandreports.com.

Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Nanotherapeutics, Inc. Snapshot 6
Nanotherapeutics, Inc. Overview 6
Key Information 6
Key Facts 6
Nanotherapeutics, Inc. - Research and Development Overview 7
Key Therapeutic Areas 7
Nanotherapeutics, Inc. - Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products - Monotherapy 11
Pipeline Products - Combination Treatment Modalities 12
Pipeline Products - Partnered Products 13
Partnered Products/Combination Treatment Modalities 14
Nanotherapeutics, Inc. - Pipeline Products Glance 15
Nanotherapeutics, Inc. - Late Stage Pipeline Products 15
Pre-Registration Products/Combination Treatment Modalities 15
Phase III Products/Combination Treatment Modalities 16
Nanotherapeutics, Inc. - Clinical Stage Pipeline Products 17
Phase II Products/Combination Treatment Modalities 17
Phase I Products/Combination Treatment Modalities 18
Nanotherapeutics, Inc. - Early Stage Pipeline Products 19
Preclinical Products/Combination Treatment Modalities 19
Nanotherapeutics, Inc. - Drug Profiles 20
influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
ross river virus vaccine 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
(buprenorphine hydrochloride + naloxone hydrochloride) 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
influenza [strain A/H9N2] vaccine 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
NTC-942 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
NTO-1151 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
ramoplanin 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
influenza [strain A/H5N1] vaccine 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
West Nile virus vaccine 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
XOMA-3AB 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
chikungunya vaccine 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
influenza [strain A/H7N9] vaccine 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
middle east respiratory syndrome vaccine + severe acute respiratory syndrome vaccine 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
norovirus (bivalent) virus like particle vaccine 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Rotavirus vaccine 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
typhoid vaccine 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Nanotherapeutics, Inc. - Pipeline Analysis 39
Nanotherapeutics, Inc. - Pipeline Products by Target 39
Nanotherapeutics, Inc. - Pipeline Products by Route of Administration 40
Nanotherapeutics, Inc. - Pipeline Products by Molecule Type 41
Nanotherapeutics, Inc. - Pipeline Products by Mechanism of Action 42
Nanotherapeutics, Inc. - Recent Pipeline Updates 43
Nanotherapeutics, Inc. - Dormant Projects 46
Nanotherapeutics, Inc. - Locations And Subsidiaries 47
Head Office 47
Other Locations & Subsidiaries 47
Appendix 48
Methodology 48
Coverage 48
Secondary Research 48
Primary Research 48
Expert Panel Validation 48
Contact Us 48
Disclaimer 49

List of Tables

Nanotherapeutics, Inc., Key Information 6
Nanotherapeutics, Inc., Key Facts 6
Nanotherapeutics, Inc. - Pipeline by Indication, 2016 8
Nanotherapeutics, Inc. - Pipeline by Stage of Development, 2016 10
Nanotherapeutics, Inc. - Monotherapy Products in Pipeline, 2016 11
Nanotherapeutics, Inc. - Combination Treatment Modalities in Pipeline, 2016 12
Nanotherapeutics, Inc. - Partnered Products in Pipeline, 2016 13
Nanotherapeutics, Inc. - Partnered Products/ Combination Treatment Modalities, 2016 14
Nanotherapeutics, Inc. - Pre-Registration, 2016 15
Nanotherapeutics, Inc. - Phase III, 2016 16
Nanotherapeutics, Inc. - Phase II, 2016 17
Nanotherapeutics, Inc. - Phase I, 2016 18
Nanotherapeutics, Inc. - Preclinical, 2016 19
Nanotherapeutics, Inc. - Pipeline by Target, 2016 39
Nanotherapeutics, Inc. - Pipeline by Route of Administration, 2016 40
Nanotherapeutics, Inc. - Pipeline by Molecule Type, 2016 41
Nanotherapeutics, Inc. - Pipeline Products by Mechanism of Action, 2016 42
Nanotherapeutics, Inc. - Recent Pipeline Updates, 2016 43
Nanotherapeutics, Inc. - Dormant Developmental Projects,2016 46
Nanotherapeutics, Inc., Other Locations 47

List of Figures

Nanotherapeutics, Inc. - Pipeline by Top 10 Indication, 2016 8
Nanotherapeutics, Inc. - Pipeline by Stage of Development, 2016 10
Nanotherapeutics, Inc. - Monotherapy Products in Pipeline, 2016 11
Nanotherapeutics, Inc. - Combination Treatment Modalities in Pipeline, 2016 12
Nanotherapeutics, Inc. - Pipeline by Target, 2016 39
Nanotherapeutics, Inc. - Pipeline by Route of Administration, 2016 40
Nanotherapeutics, Inc. - Pipeline by Molecule Type, 2016 41
Nanotherapeutics, Inc. - Pipeline Products by Mechanism of Action, 2016 42